AVTX - Avalo Therapeutics, Inc.
IEX Last Trade
9.08
0 0%
Share volume: 18,364
Last Updated: Fri 27 Dec 2024 03:16:41 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-1.15%
PREVIOUS CLOSE
CHG
CHG%
$9.08
0.00
0.00%
View ratios
Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
---|---|---|---|---|---|---|---|---|---|
Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
Report Date | 2022-08-04 | 2022-11-07 | 2023-03-29 | 2023-05-04 | 2023-08-03 | 2023-11-09 | 2024-03-29 | 2024-05-13 | |
Total revenue | 1.033 M | 14.949 M | 896.000 K | 475.000 K | 643.000 K | 236.000 K | 570.000 K | 0.000 | |
Cost of revenue | 1.567 M | 528.000 K | 619.000 K | 551.000 K | 708.000 K | 247.000 K | -222.000 K | -80.000 K | |
Gross profit | -534.000 K | 14.421 M | 277.000 K | -76.000 K | -65.000 K | -11.000 K | 792.000 K | 80.000 K | |
2,800.56% | -98.08% | -127.44% | 14.47% | 83.08% | 7,300.00% | -89.90% | |||
Operating expenses | 11.294 M | 10.326 M | 9.131 M | 8.716 M | 7.085 M | 3.739 M | 4.544 M | 5.309 M | |
Selling general and admin | 2.784 M | 3.284 M | 2.959 M | 2.708 M | 2.427 M | 2.490 M | 2.675 M | 3.193 M | |
Research and development | 8.510 M | 7.042 M | 6.172 M | 6.008 M | 4.658 M | 1.249 M | 1.869 M | 2.116 M | |
Total expenses | 12.861 M | 10.854 M | 9.750 M | 9.267 M | 7.793 M | 3.986 M | 4.322 M | 5.229 M | |
-15.61% | -10.17% | -4.95% | -15.91% | -48.85% | 8.43% | 20.99% | |||
Operating income | -11.828 M | 4.095 M | -8.854 M | -8.792 M | -7.150 M | -3.750 M | -3.752 M | -5.229 M | |
Ebit | -11.828 M | 4.095 M | -8.854 M | -8.792 M | -7.150 M | -3.750 M | -3.752 M | -5.229 M | |
Pretax income | -12.982 M | 3.197 M | -9.803 M | -9.947 M | -8.186 M | -5.220 M | -8.177 M | -121.283 M | |
-124.63% | -406.63% | 1.47% | -17.70% | -36.23% | 56.65% | 1,383.22% | |||
Income tax | 5.000 K | 5.000 K | 9.000 K | 8.000 K | 7.000 K | 8.000 K | -9.000 K | 7.000 K | |
Net income basic | -12.987 M | 3.192 M | -9.812 M | -9.955 M | -8.193 M | -5.228 M | -8.168 M | -121.290 M | |
124.58% | -407.39% | -1.46% | 17.70% | 36.19% | -56.24% | -1,384.94% | |||
Net income | -12.987 M | 3.192 M | -9.812 M | -9.955 M | -8.193 M | -5.228 M | -8.168 M | -121.290 M | |
124.58% | -407.39% | -1.46% | 17.70% | 36.19% | -56.24% | -1,384.94% |